Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 23;44(1):257.
doi: 10.1007/s10792-024-03192-9.

Update on lacrimal apparatus dysfunction associated with differentiated thyroid cancer after I-131 therapy

Chunlan Liang  1 , Changlin Wu  1 , Lian Liu  2 , Jingxiang Zhong  3
Affiliations
Review

Update on lacrimal apparatus dysfunction associated with differentiated thyroid cancer after I-131 therapy

Chunlan Liang et al. Int Ophthalmol. .

Abstract

Purpose: The most prevalent lacrimal apparatus dysfunctions associated with differentiated thyroid cancer(DTC) after I-131 therapy are dry eye and nasolacrimal duct obstruction(NLDO), leading to ocular discomfort and lower quality of life for patients. It is crucial to diagnose and manage lacrimal apparatus dysfunction associated with I-131 therapy for DTC. Therefore, this review aims to comprehensively summarize and analyze the advances in mechanisms and therapeutic options underlying lacrimal apparatus dysfunction induced by I-131 therapy for DTC.

Methods: A comprehensive search of CNKI, PubMed, and Wed of Science was performed from the database to December of 2023. Key search terms were "Thyroid cancer", "I-131", "Complications", "Dry eye", "Epiphora", "Tear", "Nasolacrimal duct" and "NLDO".

Results: The research indicates that I-131 therapy for DTC causes damage to the lacrimal glands and nasolacrimal duct system, resulting in symptoms such as dry eye, epiphora, and mucoid secretions. Moreover, recent research has focused on exploring relevant risk factors of the condition and experimental and clinical treatments. However, there is some controversy regarding the mechanisms involved, whether it is due to the passive flow of I-131 in tears, active uptake of I-131 by the sodium-iodide symporter (NIS) in the lacrimal sac and nasolacrimal duct, or secondary metabolic and hormonal disturbances caused by I-131.

Conclusion: It is crucial for early detection and preventive measures by ophthalmologists and the need for further studies to elucidate the mechanisms underlying the disease.

Keywords: DTC; Dry eye; I-131 therapy; NIS; NLDO; Therapies.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Vaccarella S, Dal Maso L, Laversanne M et al (2015) The impact of diagnostic changes on the rise in thyroid Cancer incidence: a Population-based study in selected high-resource countries. Thyroid 25(10):1127–1136. https://doi.org/10.1089/thy.2015.0116 - DOI - PubMed
    1. Rahib L, Smith BD, Aizenberg R et al (2014) Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74(11):2913–2921. https://doi.org/10.1158/0008-5472.Can-14-0155 - DOI - PubMed
    1. Chiapponi C, Hartmann MJM, Decarolis B et al (2023) Differentiated thyroid cancer in adolescents: single center experience and considerations for surgical management and radioiodine treatment. J Clin Res Pediatr Endocrinol 15(3):257–263. https://doi.org/10.4274/jcrpe.galenos.2023.2023-1-16 - DOI - PubMed - PMC
    1. Riesco-Eizaguirre G, Santisteban P (2006) A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155(4):495–512. https://doi.org/10.1530/eje.1.02257 - DOI - PubMed
    1. Guidelines Working Committee of Chinese Society of Clinical Oncology (2021) Guidelines of Chinese society of clinical 0ncology (CSCO) dilerentiated thyroid Cancer. Cancer Control Treat. 34(12):1164–1201. https://doi.org/10.3969/j.ssn.1674-0904.2021.12.013 - DOI

MeSH terms

LinkOut - more resources